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Abstract
The most prevalent neurological disorders of myelin include perinatal brain injury leading to cerebral palsy in infants and 
multiple sclerosis in adults. Although these disorders have distinct etiologies, they share a common neuropathological feature 
of failed progenitor differentiation into myelin-producing oligodendrocytes and lack of myelin, for which there is an unmet 
clinical need. Here, we reveal that a molecular pathology common to both disorders is dysregulation of activin receptors 
and that activin receptor signaling is required for the majority of myelin generation in development and following injury. 
Using a constitutive conditional knockout of all activin receptor signaling in oligodendrocyte lineage cells, we discovered 
this signaling to be required for myelination via regulation of oligodendrocyte differentiation and myelin compaction. These 
processes were found to be dependent on the activin receptor subtype Acvr2a, which is expressed during oligodendrocyte 
differentiation and axonal ensheathment in development and following myelin injury. During efficient myelin regeneration, 
Acvr2a upregulation was seen to coincide with downregulation of Acvr2b, a receptor subtype with relatively higher ligand 
affinity; Acvr2b was shown to be dispensable for activin receptor-driven oligodendrocyte differentiation and its overexpres-
sion was sufficient to impair the abovementioned ligand-driven responses. In actively myelinating or remyelinating areas 
of human perinatal brain injury and multiple sclerosis tissue, respectively, oligodendrocyte lineage cells expressing Acvr2a 
outnumbered those expressing Acvr2b, whereas in non-repairing lesions Acvr2b+ cells were increased. Thus, we propose 
that following human white matter injury, this increase in Acvr2b expression would sequester ligand and consequently impair 
Acvr2a-driven oligodendrocyte differentiation and myelin formation. Our results demonstrate dysregulated activin recep-
tor signaling in common myelin disorders and reveal Acvr2a as a novel therapeutic target for myelin generation following 
injury across the lifespan.
Keywords Myelin · Remyelination · Oligodendrocyte · Multiple sclerosis · Perinatal brain injury · Activin receptor
Introduction
Myelin ensures axon health and function in the CNS via 
trophic/metabolic support and insulation for electrical 
impulse conduction [14, 16, 26, 32, 37, 46]. The lack of 
myelin is, therefore, associated with axon dysfunction and/or 
loss, causing deficits in movement, sensation, and cognition, 
as observed in prevalent myelin disorders of development 
(perinatal brain injury leading to cerebral palsy/cognitive 
deficits) and adulthood [multiple sclerosis (MS)]. Although 
these have distinct etiologies, a shared neuropathological 
feature involves failed differentiation of oligodendrocyte 
precursor cells (OPCs) into myelin-producing oligoden-
drocytes following injury, resulting in impaired myelin 
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formation (myelination) [8, 10, 33, 36, 57] or regeneration 
(remyelination) [38], respectively. However, the mechanisms 
underpinning this pathology are not fully understood, as evi-
denced by the lack of approved therapies aimed at promoting 
oligodendrocyte differentiation and myelin generation.
Our previous work identified activin-A, a member of 
the transforming growth factor beta (TGF-β) superfamily, 
as being a promising pro-differentiation therapeutic target 
[45]. We found that at the onset of remyelination of focally 
demyelinated white matter lesions, microglia/macrophages 
express activin-A, and oligodendrocyte lineage cells express 
the ligand-binding activin receptors (Acvr2a, Acvr2b) and 
the signal-transducing co-receptor (Acvr1b) [45]; depletion 
of these microglia/macrophages caused impairment of remy-
elination [45]. In addition, healthy developmental myelina-
tion has recently been shown to be regulated by other TGF-β 
family members, TGF-β1 and activin-B [19, 49], albeit pri-
marily via signaling through distinct receptors (TGFβR1) or 
co-receptors (Acvr1c), respectively. However, how activin 
receptor signaling regulates oligodendroglial lineage cell 
behavior, and whether this is required for myelination and 
remyelination, remains to be fully elucidated.
Here, we reveal the requirement for activin receptor sign-
aling in regulating oligodendrocyte lineage cell responses 
during healthy white matter development and following 
injury. Furthermore, we demonstrate how dysregulation of 
activin receptor expression underpins myelin pathology in 
human perinatal brain injury and multiple sclerosis, reveal-
ing potentially targetable receptors for clinical intervention 
in myelin disorders across the lifespan.
Materials and methods
Animals
All experiments were performed under UK Home Office 
project licenses issued under the Animals (Scientific Pro-
cedures) Act. Animals were housed at 6 animals per cage 
in a 12 h light/dark cycle with unrestricted access to food 
and water. For animal experiments, power was calculated by 
two-sided 95% confidence interval via the normal approxi-
mation method using OpenEpi software, and reached > 80% 
power (84–100%) for all experiments. ARRIVE guidelines 
were followed in providing details of experiments, quantifi-
cations, and reporting.
Organotypic cerebellar slice cultures
Postnatal day 0–2 (P0-P2) CD1 pup cerebellum and attached 
hindbrains were sagittally sectioned at 300 µm on a McIl-
wain tissue chopper and plated onto Millipore-Millicel-CM 
mesh inserts (Fisher Scientific) in 6-well culture plates at 
six slices per insert. Media was composed of 50% minimal 
essential media, 25% heat-inactivated horse serum, 25% Ear-
le’s balanced salt solution (all from GIBCO), 6.5 mg ml−1 
glucose (Sigma), 1% penicillin–streptomycin, and 1% glu-
tamax. At 21 days in vitro when myelination is complete 
and compact, demyelination was induced by incubation in 
0.5 mg ml−1 lysolecithin (Sigma) for 18-20 h. Slices were 
then washed in media for 10 min and treated at 2 days post 
lysolecithin (dpl) until 7, 10, or 14 dpl with activin-A (100 
ng ml−1, R&D Systems), inhibin-A (100 ng  ml−1, R&D Sys-
tems) or vehicle controls. Slices were fixed in 4% paraform-
aldehyde (PFA, wt/vol) for 10 min and blocked in 5% nor-
mal horse serum (GIBCO) and 0.3% Triton-X-100 (Fisher 
Scientific) for 1 h. Primary antibodies rat anti-MBP (1:250, 
AbD Serotec; MCA409S) and chicken anti-neurofilament-
H (1:10,000, EnCor Biotech; CPCA-NF-H) were applied 
for 48 h at 4 °C. Slices were washed twice in 0.1% Triton-
X-100 and fluorescently conjugated antibodies applied for 
2 h at 20–25 °C (Life Technologies-Molecular Probes). Fol-
lowing counterstaining with Hoechst, slices were washed 
thrice and mounted onto glass slides using Fluoromount-
G. Z-stacks were captured using an Olympus 3i Spinning 
Disk microscope (60× silicone objective) and SlideBook 
software. Stacks were cropped to 14 slices (0.59 µm/slice) 
in SlideBook (3i), and images blinded and imported into 
Volocity (Perkin Elmer) as an image sequence. Remyelina-
tion index was calculated by normalizing voxel counts of 
values of co-localization of myelin (MBP) and axon (NF) to 
NF voxel counts, and this value for treated slices was further 
normalized to vehicle controls. Both males and females were 
assessed.
Breeding strategy for conditional knockout 
generation
Sperm from Acvr1b LoxP mice was generously provided by 
Dr. Gloria H. Su (Columbia University) where exons 2–3 are 
flanked with Cre-LoxP sites, which upon Cre recombination 
causes deletion of a 3.3-kb sequence, frameshift mutation, 
and abolishment of Acvr1b protein expression [53]. Sperms 
were injected into pseudopregnant C57Bl/6J females. The 
offspring were intercrossed to generate mice homozygous for 
the LoxP allele and subsequently crossed to PDGFRa-Cre 
mice (Jax laboratories, 013148). Mice identified as being 
positive for PDGFRa-Cre and heterozygous for the LoxP 
allele were then crossed back to homozygous Acvr1b LoxP 
mice to generate homozygous conditional knockout (cKO) 
mice. Mice were confirmed as a cKO by performing PCR 
on the genomic DNA for detection of the Cre recombinase 
gene and homozygosity of the Acvr1b LoxP allele. Further 
analysis of the recombination by PCR and Cre recombinase 
immunohistochemistry in the corpus callosum confirmed 
the conditional status of these mice (Online Resource 
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Supplemental Fig. 1). This was confirmed by DNA extrac-
tion from cortical OPCs of transgenic mice using the Wizard 
SV genomic purification system (Promega) and PCR using 
Q5 High Fidelity DNA Polymerase (New England Biolabs) 
using amplification with primers P4 and P5 (sequence in 
genotyping section below) (Online Resource Supplemental 
Fig. 1). Both males and females were assessed.
Genotyping
Genomic DNA was extracted from ear tissue using the Wiz-
ard SV genomic purification system (Promega) according 
to the manufacturer’s instructions. Acvr1b floxed mice were 
genotyped using PCR strategies as previously described 
[53]. Briefly, Acvr1b floxed mice were genotyped using 
primers P1 (ATG AAA AGT GCT TGC GTG TG) and P2 
(CAG GGA AGG GCA GAT ATC AA). PDGFRa-Cre mice 
were genotyped using primers 1084 (GCG GTC TGG CAG 
TAA AAA CTATC), 1085 (GTG AAA CAG CAT TGC TGT 
CACTT), 7338 (CTA GGC CAC AGA ATT GAA AGA TCT ) 
and 7339 (GTA GGT GGA AAT TCT AGC ATC ATC C). Cre-
mediated recombination was detected using P4 (CCA GCA 
CCT ACA TCA CAT GG) and P5 (CTC TAT GGA GAG CAC 
CCT CTTTG) (Online Resource Supplemental Fig. 1).
Immunohistochemistry of rodent cryosections
Animals were intracardially perfused with 4% PFA (wt/
vol; Sigma), brains post-fixed overnight and cryoprotected 
in sucrose prior to embedding in OCT (Tissue-Tech) and 
storage at − 80 °C. 8–10 μm cryosections were air-dried, 
permeabilized and blocked for 1 h with 5% normal horse 
serum (GIBCO) and 0.3% Triton-X-100 (Fisher Scientific). 
For Caspr staining, blocking solution and antibody diluent 
was composed of 10% normal horse serum and 0.1% Triton-
X-100. For myelin protein staining, sections were permeabi-
lized in methanol at − 20 °C for 10 min. For Olig1 and Olig2 
staining, sections were permeabilized in Vector Unmasking 
Solution (Vector) by microwaving for 5 min followed by a 
30-min incubation at 60 °C. Primary antibodies were applied 
overnight at 4 °C in a humid chamber and include rat anti-
MBP (AbD Serotec, 1:250; MCA409S), mouse anti-MAG 
(Millipore, 1:100; MAB1567), mouse anti-Olig2 (Milli-
pore, 1:100; MABN50), rabbit anti-Olig2 (1:100, Millipore; 
AB960), mouse anti-Olig1 (Millipore, 1:100; MAB5540), 
mouse anti-NG2 (1:200, Millipore; MAB5384), mouse anti-
CC1 (1:100, Abcam; ab16794), rabbit anti-Caspr (1:500, 
Abcam; ab34151), rabbit anti-cleaved caspase-3 (1:500, BD 
Pharmingen; 559565), rabbit anti-Acvr2a (1:100, Abcam; 
ab135634), goat anti-Acvr2a (1:40, RnD Biosystems; 
AF340), rabbit anti-Acvr2b (1:100, Abgent; AP7105a). 
Fluorescently conjugated secondary antibodies were 
applied for 2 h at 20–25 °C in a humid chamber (1:500, Life 
Technologies-Molecular Probes). Following counterstaining 
with Hoechst, slides were coverslipped with Fluoromount-
G (Southern Biotech). Antibody isotype controls added to 
sections at the same final concentration as the respective 
primary antibodies showed little or no nonspecific stain-
ing. Terminal deoxynucleotidyl transferase dUTP nick end 
labeling (TUNEL; Promega) assay for apoptosis was carried 
out according to the manufacturer’s instructions; DNase I 
(10 units ml−1) was applied as a positive control for double 
stranded breaks. Sections were imaged on a Leica SPE con-
focal microscope (40× objective) or an Olympus 3i Spinning 
Disk microscope (30×, 60×, or 100× oil immersion objec-
tives). Intensity of MAG or MBP staining in selected white 
matter areas was determined using the Histogram function 
in Adobe Photoshop and normalized to background levels 
in a non-white matter area from the respective sample. Per-
centage area of NF co-localizing with Caspr was calculated 
using Volocity software.
Western blotting
CNS samples were lysed with RIPA buffer (Thermo Scien-
tific) supplemented with 1% protease inhibitor cocktail set III 
ethylenediaminetetraaceticacid (EDTA)-free (Calbiochem). 
Protein concentrations were determined using the Pierce 
BCA Protein Assay Kit (according to the manufacturer’s 
instructions). Samples were diluted in Laemmli buffer (Bio-
Rad) and 5% β-mercaptoethanol (Sigma)], heated at 95 °C 
for 2 min, and 10 µg of protein was loaded onto an acryla-
mide gel (4–20%; Thermo Scientific). Gel electrophoresis 
was performed in tris-hydroxyethyl piperazineethanesulfonic 
acid (HEPES)-sodium dodecyl sulfate (SDS) running buffer 
(Thermo Scientific) at 100 V and proteins transferred onto 
polyvinylidene difluoride (PVDF) membranes (Millipore) 
for 2 h at 10 V in 10% transfer buffer [3% Tris–HCl (Sigma-
Aldrich), 15% glycine (Sigma-Aldrich), pH 8.3] and 20% 
methanol (Fisher Chemical) diluted in water. Membranes 
were blocked with 4% bovine serum albumin in Tris-buff-
ered saline (TBST) [4% sodium chloride (NaCl), 0.1% potas-
sium chloride (KCl), 1.5% Tris–HCl, 0.1% Tween-20 (all 
from Sigma-Aldrich), pH 7.4] for 1 h at room temperature on 
an orbital shaker, then incubated overnight at 4 °C with rab-
bit anti-MBP (1:1000, AB980; Merck Millipore) or mouse 
anti-CNPase (1:1000, AMAb91068; Atlas Antibodies). 
Membranes were washed thrice in TBST for 5 min and incu-
bated with horseradish peroxidase (HRP)-IgG secondary 
antibody conjugates (1:2000; Calbiochem) for 1 h at room 
temperature. Chemiluminescent substrate detection reagent 
RapidStep ECL Reagent (Calbiochem) was used to visualize 
bands. For loading control purposes, all membranes were 
re-blotted with anti-mouse or anti-rabbit beta-Actin.
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Resin embedding, semi‑thin sections, and electron 
microscopy
Mice were intracardially perfused with 4% PFA (wt/vol) and 
2% glutaraldehyde (vol/vol; TAAB Laboratories) in 0.1 M 
phosphate buffer. Tissue was post-fixed overnight at 4 °C 
and transferred to 1% glutaraldehyde (vol/vol) until embed-
ding. 1 mm tissue sections were processed into araldite resin 
blocks. 1 μm microtome-cut sections were stained with a 1% 
toluidine blue/2% sodium borate solution prior to bright field 
imaging at 100× magnification using a Zeiss Axio micro-
scope. Number of myelinated axons was blindly quantified 
in 50 μm × 50 μm images of corpus callosum, with 2–4 sec-
tions counted per mouse and then values averaged. Ultrathin 
sections (60 nm) were cut from corpus callosum, stained in 
uranyl acetate and lead citrate, and grids imaged on a JEOL 
Transmission Electron Microscope. Axon diameter, myelin 
thickness, and inner tongue thickness were calculated from 
measured area based on assumption of circularity using Fiji/
ImageJ (Fiji.sc) (diameter = 2 × √[area/π]), with a mini-
mum of 100 axons per animal analyzed. Enlarged inner 
tongues in conditional knockout mice precluded standard 
g-ratio analysis of myelin thickness, which was instead cal-
culated by subtracting the diameter to the innermost compact 
myelin layer from the diameter to the outermost compact 
myelin layer (see Online Resource Supplemental Fig. 5 for 
outline of quantification methods). Inner tongue thickness 
was calculated by subtracting the axonal diameter from the 
diameter to the innermost compact layer (Online Resource 
Supplemental Fig. 5). ‘Proportion of myelinated axons’ per 
axon diameter was determined by plotting the proportion 
of total myelinated axons (across all axons diameters) from 
each animal that were of a specific diameter, which was fit-
ted with a best-fit polynomial regression.
Oligodendrocyte lineage cell cultures
Cortical mixed glial cultures generated from both male and 
female Sprague–Dawley rat P0–P2 pups were expanded for 
10–14 days in vitro, and microglia depleted by de-adhesion 
following 1 h on a rotary shaker at 37 °C at 250 rpm. OPCs 
were subsequently isolated from collection of the floating 
fraction following 16 h on the rotary shaker, followed by 
depletion of contaminating astrocytes by differential adhe-
sion. OPCs were plated in DMEM containing 4.5 g l−1 glu-
cose, l-glutamine, pyruvate, SATO [16 µg ml−1 putrescine, 
400 ng ml−1 l-thyroxine, 400 ng ml−1 tri-iodothyroxine, 
60 ng ml−1 progesterone, 5 ng ml−1 sodium selenite, 100 
µg ml−1 bovine serum albumin fraction V, 10 µg ml−1 insu-
lin, 5.5 µg ml−1 halo-transferrin (all from Sigma-Aldrich)], 
0.5% fetal calf serum (GIBCO), 1% penicillin/streptomycin, 
10 ng ml−1 platelet-derived growth factor, and 10 ng ml−1 
fibroblast growth factor-2, at 2 × 104 cells per well in 8-well 
PDL-coated permanox chamberslides (Lab-TEK). OPCs 
were treated with activin-A (10 ng ml−1, R&D Systems) 
or vehicle control (0.0002% BSA) for 3 days. In a subset of 
experiments, OPCs were co-treated with activin-A and neu-
tralizing antibodies against Acvr2a or Acvr2b (30 μg ml−1, 
R&D Systems; AF340, AF339) or goat IgG isotype con-
trol (30 μg ml−1, Santa Cruz Biotechnology). Cells were 
matured to oligodendrocytes by withdrawal of growth fac-
tors from the media and treated with activin-A or vehicle 
control, with or without neutralizing antibodies for 5 days 
as above. An average of 120 cells were counted per image, 
with 2 images assessed per condition per biological replicate 
(a total of > 700 cells quantified per condition); values were 
averaged per biological sample. For quantification of mature 
oligodendrocyte membrane area, images were imported 
into Columbus software (Perkin Elmer), individual cells 
identified (by the software) by Hoechst, oligodendrocytes 
identified by MBP staining, and size of cytoplasm meas-
ured in square pixels  (px2) with a threshold of 2000  px2 
set to exclude background/false positives. For Phalloidin 
intensity measurements, Columbus was used to first iden-
tify cells (Hoechst+ nuclei) then mature oligodendrocytes 
(MBP+), and Phalloidin signal intensity was measured in 
each MBP+ cell.
Immunocytochemistry
Cells were fixed with 4% PFA (wt/vol) for 10–15 min and 
blocked for 30 min in 10% goat serum (Sigma), 2% horse 
serum (GIBCO), and 0.3% Triton-X-100 at 20–25  °C. 
Primary antibodies were diluted in blocking solution and 
applied for 1 h at 20–25 °C, and included mouse anti-MAG 
(1:100, Millipore; MAB1567), rat anti-MBP (1:250; AbD 
Serotec; MCA409S), and chicken anti-GFP (1:100; Abcam; 
ab13970). Cells were incubated with fluorescently conju-
gated secondary antibodies diluted in blocking solution 
(1:1000, Life Technologies-Molecular Probes), and in a 
subset of experiments with Phalloidin-Alexa-568 (1:40; 
ThermoFisher), for 1 h at 20–25 °C. Slides were counter-
stained with Hoechst (5 µg ml−1) and coverslipped with 
Fluoromount-G. Cells were imaged on a Leica SPE confo-
cal microscope (40× objective) or an Olympus 3i Spinning 
Disk microscope (30× or 60× objectives).
Lentiviral‑based overexpression
Lentivirus particles generated using 3rd generation lenti-
virus packaging were purchased from Insight Bio/Origene 
(stock  107 TU ml−1), inducing expression of GFP only for 
control transfection (PS100071V), or inducing overexpres-
sion of mouse Acvr2b and GFP (MR212153L2V). Particles 
were added to cultures of OPCs or differentiating oligoden-
drocytes at a multiplicity of infection (MOI) of 2.5 for 3 
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or 5 days, respectively. Cells were then fixed and immu-
nostained or lysed for protein as above.
Microfiber myelination assays
OPCs were plated onto PDL-coated parallel-aligned 2 μm 
electrospun poly-l-lactide acid (PLLA) fibers in 12-well 
plate inserts (The Electrospinning Company) at 35,000 cells 
per insert, as done previously [7]. Media was composed of 
50:50 Neurobasal media and DMEM with high glucose sup-
plemented with SATO [16 µg ml−1 putrescine, 400 ng ml−1 
l-thyroxine, 400 ng ml−1 tri-iodothyroxine, 60 ng ml−1 pro-
gesterone, 5 ng ml−1 sodium selenite, 100 µg ml−1 bovine 
serum albumin fraction V, 10 µg ml−1 insulin, 5.5 µg ml−1 
halo-transferrin), 5 µg ml−1 N-acetyl cysteine, 10 ng ml−1 
d-Biotin (all from Sigma-Aldrich)], ITS supplement 
(Sigma), B27 (Invitrogen), and 1% penicillin/streptomy-
cin. Cultures were treated with activin-A (1–100 ng ml−1, 
R&D Systems) or vehicle control for 14 days, fixed with 4% 
paraformaldehyde (wt/vol, Sigma), permeabilized with 0.1% 
Triton-X-100 (Fisher Scientific) and incubated overnight 
at 4 °C with rat anti-MBP antibody (1:250, AbD Serotec; 
MCA409S). Following three washes in PBS, inserts were 
incubated with secondary antibody (1:1000, Life Technolo-
gies-Molecular Probes) for 1 h at 20–25 °C, counterstained 
with Hoechst and mounted onto glass coverslips with Fluo-
romount G. Inserts were imaged as Z-stacks on an Olympus 
3i Spinning Disk microscope (60×). Myelin sheath number 
per oligodendrocyte and lengths from 20 oligodendrocytes 
per biological preparation were analyzed in a blinded man-
ner using the segmented line tool in Fiji/ImageJ (Fiji.sc) on 
maximum intensity images, using Z stacks to confirm com-
plete wrapping around fibers.
Forward phase phospho‑antibody microarray
OPCs were plated at 1 × 106 cells per well in a 6-well PDL-
coated plate and treated with activin-A (10 ng ml−1) or vehi-
cle control (0.0002% BSA). Cultures were washed with cold 
phosphate buffered saline on ice, scraped, and centrifuged 
thrice at 10,000 rpm at 4 °C and supernatant discarded. Pro-
tein extraction, lysate purification, and protein biotinylation 
were performed using the Antibody Array Assay Kit (Full 
Moon Biosystems) according to the manufacturer’s instruc-
tions. Samples were applied to TGF-β phospho-antibody 
microarray slides (Full Moon Biosystems) which have 176 
immobilized antibodies against phosphorylated and unphos-
phorylated specific residues in proteins associated with the 
5 TGFβ signaling pathways, with 6 technical replicates per 
antibody. All antibodies are against activating phospho-
rylation states, to the exception of Abl Thr754/735, GEF2 
Ser885, Cofilin Ser3, Myc Ser373/Ser62/Thr358/Thr58. 
Following incubation with streptavidin-Cy3 (1:1000), signal 
was detected on an Axon4200 microarray scanner (Edin-
burgh Genomics, The University of Edinburgh). Subsequent 
to background signal subtraction, values from phosphoryl-
ated signal were normalized to total protein signal for each 
protein site, then normalized to vehicle control. Data were 
then Log2 transformed and plotted as heat maps using 
GraphPad Prism 7 (San Diego, USA).
In vivo focal demyelinated lesions
Demyelinating lesions were induced in the caudal cerebel-
lar peduncles of 12-week-old female Sprague–Dawley rats 
by stereotaxic injection of 4 µl of 0.01% ethidium bromide 
(vol/vol) using a Hamilton syringe. Rats were intracardially 
perfused with 4% PFA, cryoprotected, cryosectioned, and 
stained as above. Non-lesioned CCP served as a control.
Post‑mortem brain tissue
Formalin-fixed paraffin-embedded post-mortem perinatal 
brain injury tissue was obtained with full ethical approval 
from the Medical Research Council Edinburgh Brain and 
Tissue Bank (EBTB) (REC/1-/S1402/69). Tissue with 
evidence of white matter injury was selected with neuro-
pathological support from Dr. Julie-Clare Becher (Royal 
Infirmary of Edinburgh) and Dr. Colin Smith (University 
of Edinburgh) (Table S1, Online Resource Supplemental 
Fig. 9a–c). Sections were de-paraffinized twice at 20–25 °C 
in Histoclear for 10 min then rehydrated through an ethanol 
gradient (100% (twice), 95, 70, and 50%, 5 min each). Fol-
lowing washes in 0.1% Tween20 (vol/vol) in Tris-buffered 
Saline (TBS), sections were microwaved in Vector Unmask-
ing Solution for 10 min, washed once, and endogenous phos-
phatase and peroxidase activity blocked for 5 min (Bloxall, 
Vector). Primary antibody was prepared in 2.5% Normal 
Horse Serum (Vector) and applied overnight in a humid 
chamber at 4 °C. Antibodies used included mouse CD68 
(1:100, DAKO; M0814), rat anti-MBP (AbD Serotec, 1:250; 
MCA409S), rabbit anti-INHBA (activin-A subunit; 1:100, 
Sigma-Aldrich; HPA020031), rabbit anti-Acvr2a (1:100, 
Abcam; ab135634), rabbit anti-Acvr2b (1:100, Abgent; 
AP7105a), rabbit anti-PCNA (1:400, Abcam; ab18197), and 
mouse anti-Olig2 (1:100, EMD Millipore; MABN50). Fol-
lowing washes, alkaline phosphatase-conjugated anti-mouse 
or anti-rabbit secondary antibody was applied for 30 min at 
20–25 °C in a humid chamber. Sections were washed in TBS 
and stains visualized by Vector Blue substrate kit according 
to the manufacturer’s instructions (maximum 15 min). For 
co-staining, sections were washed thrice and re-blocked to 
quench any remaining phosphatase activity (Bloxall, Vec-
tor) prior to application of primary antibody, then developed 
using Vector Red substrate kit according to the manufac-
turer’s instructions (maximum 15 min). Following washes 
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in water, the sections were counterstained with Hoechst and 
mounted with Fluoromount-G. Entire tissue sections were 
imaged using a Zeiss AxioScan SlideScanner. Due to non-
neurological age-matched controls not being available, areas 
of injury (high CD68 densities; average 122 ± 30 cells/mm2) 
were compared to areas of non-injury (low CD68 densities; 
average 10 ± 10 cells/mm2) within the same section (pathol-
ogy assessment shown in Online Resource Supplemental 
Fig. 9a–c). Lesion maps were defined for analysis in Zeiss 
Zen2 software; fields of 360 μm × 360 μm were counted per 
sample (injured or non-injured) and counts were multiplied 
to determine density of immunopositive cells per  mm2. Post-
mortem tissue from MS patients and controls who died of 
non-neurological causes were obtained via a UK prospective 
donor scheme with full ethical approval from the UK Multi-
ple Sclerosis Tissue Bank (MREC/02/2/39). MS diagnosis 
was confirmed by neuropathological means by F. Roncaroli 
(Imperial College London) and clinical history was provided 
by R. Nicholas (Imperial College London). Snap frozen 
unfixed tissues blocks (2 × 2 × 1 cm) were cut at 10 µm 
and stored at − 80 °C. MS lesions were classified according 
to the International Classification of Neurological Disease 
using Luxol Fast Blue staining and Oil Red O immunore-
activity using standard methods (pathological assessment 
shown in Online Resource Supplemental Fig. 9d–f). We 
analyzed 4 control blocks and 10 tissue blocks from 8 MS 
patients (Table S2). Sections were fixed in 4% PFA for 1 h 
at 20–25 °C, washed in TBS and permeabilized in methanol 
for 10 min at − 20 °C. Sections were subsequently stained, 
imaged and quantified as above.
Statistics
All manual cell counts were performed in a blinded man-
ner. Data are represented as mean ± s.e.m. Power calcula-
tions for sample size were performed (using OpenEpi), and 
showed power between 84 and 100% for all experiments. 
Statistical tests include one-sample t test for data where val-
ues were normalized to control, two-tailed Student’s t test or 
Mann–Whitney test, and non-parametric one-way ANOVA 
(Kruskal–Wallis) with Dunn’s multiple comparison post hoc 
test when > 3 comparisons were made. A paired Student’s t 
test was used when variation between experiments was high, 
to normalize to baseline levels within each biological prep-
aration. Slopes of myelin thickness versus axon diameter 
were compared using the Extra Sum of Squares F test. Curve 
distributions of proportion of myelinated axons per axon 
diameter were compared using the Kolmogorov–Smirnov 
test. Proportions of CC1+ or CC1− negative cells within the 
Olig2+ population were compared using Multiple t tests and 
two stage step up linear procedure of Benjamini, Krieger, 
and Yekutieli with a false discovery rate of 1%. P < 0.05 
was considered to be statistically significant. Data handling 
and statistical processing were performed using Microsoft 
Excel and GraphPad Prism Software.
Results
Activin receptor signaling is required 
for developmental myelination
To determine whether activin receptor signaling is required 
for developmental myelination, we sought to constitutively 
eliminate all activin receptor signaling in oligodendrocyte 
lineage cells. We achieved this by targeting Acvr1b, the 
activin co-receptor that is required for all intracellular sig-
nal transduction downstream of activin-A binding to either 
activin receptor Acvr2a or Acvr2b [6] (Fig. 1a). We thus 
created a constitutive conditional knockout in which oli-
godendroglial lineage cells cannot respond to any activin 
receptor ligation due to Acvr1b excision in OPCs (PDGFRa-
Cre;  Acvr1bfl/fl) [6, 53] (Fig. 1a; Online Resource Supple-
mental Fig. 1a–c). By immunofluorescence, Cre expression 
was confirmed to be in Olig2+ oligodendrocyte lineage cells 
(Online Resource Supplemental Fig. 1d). At postnatal day 
16 (P16) when myelination is normally underway, PDGFRa-
Cre;  Acvr1bfl/fl mice displayed a tremor, hunched posture, 
and a stiff tail (Online Resource Supplemental Video 1), all 
behaviors associated with myelin abnormalities [17, 44] or 
damage (e.g. in experimental autoimmune encephalomyeli-
tis) [12, 58].
To determine whether this reflected myelin pathol-
ogy, we assessed myelin-associated protein expression 
in the brains of  Acvr1bfl/fl control and PDGFRa-Cre; 
 Acvr1bfl/fl mice by Western blot and observed a decrease 
in 2′,3′-cyclic nucleotide 3′-phosphodiesterase (CNP) and 
myelin basic protein (MBP) in the conditional knockout 
mice (Fig. 1b). We further analyzed expression of myelin 
protein by immunofluorescence in multiple white matter 
tracts (corpus callosum, cerebellum, spinal cord) in PDG-
FRa-Cre;  Acvr1bfl/fl mice and observed a severe reduction 
in myelin-associated glycoprotein (MAG) intensity com-
pared to  Acvr1bfl/fl control and heterozygous (PDGFRa-
Cre;  Acvr1bfl/+) littermates (Fig. 1c, d; Online Resource 
Supplemental Fig. 2a, b). Hypomyelination in PDGFRa-
Cre;  Acvr1bfl/fl mice was further verified by histological 
analysis of semi-thin resin sections, which showed a sig-
nificantly reduced density of myelinated axons by 60% 
(Fig. 1e, f). Peripheral nervous system myelin on dorsal 
root ganglia was unaffected in conditional knockout mice 
(Online Resource Supplemental Fig. 2c, d), as expected 
given the absence of PDGFRα expression in that com-
partment. Ultrastructural assessment of the sparse myelin 
that was produced by P16 in PDGFRa-Cre;  Acvr1bfl/fl 
mice revealed that of all the myelinated axons, the largest 
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Fig. 1  Activin receptor signal-
ing is required for develop-
mental myelination. a Diagram 
of activin receptor signaling: 
Acvr2a and Acvr2b are ligand-
binding receptors that require 
Acvr1b to induce intracellular 
signallng. In PDGFRa-Cre; 
 Acvr1bfl/fl mice, the knock-
out of Acvr1b eliminates all 
activin receptor signaling from 
both ligand binding recep-
tors. b Western blots of brain 
lysates from P16  Acvr1bfl/fl and 
PDGFRa-Cre;  Acvr1bfl/fl mice 
(cerebellum) labeled for CNP 
(46 kDa) or MBP (14–21 kDa) 
with β-Actin as a loading con-
trol. c Images of corpus callo-
sum, cerebellum [counterstained 
with Hoechst (blue)] and dorsal 
spinal cord in P16  Acvr1bfl/
fl and PDGFRa-Cre;  Acvr1bfl/fl 
mice immunostained for myelin 
protein MAG (green). Scale 
bar 25 μm. d Mean MAG 
intensity normalized to back-
ground ± s.e.m. in the corpus 
callosum of P16  Acvr1bfl/
fl (n = 4 mice), PDGFRa-
Cre;  Acvr1bfl/+ (n = 4 mice) 
and PDGFRa-Cre;  Acvr1bfl/fl 
mice (n = 6 mice). Two-tailed 
Student’s t test, *P = 0.0211, 
**0.0018. e Mean number of 
myelinated fibers ± s.e.m. per 
field of toluidine-blue stained 
semi-thin resin sections of 
corpus callosum at P16 in 
 Acvr1bfl/fl and PDGFRa-Cre; 
 Acvr1bfl/fl mice (n = 3 mice per 
group). Two-tailed Student’s t 
test, **P = 0.0034. f Toluidine-
blue stained semi-thin resin 
sections of corpus callosum in 
 Acvr1bfl/fl (left) and PDGFRa-
Cre;  Acvr1bfl/fl mice (right), 
with expanded field of view 
(f(a) and f(b), respectively). 
Scale bar 20 μm. g Analysis of 
distribution of myelinated axons 
in relation to axon diameter, 
represented as proportion of 
myelinated axons only (from 
all diameters), in  Acvr1bfl/fl 
(magenta) and PDGFRa-Cre; 
 Acvr1bfl/fl mice (green) mice 
(n = 3 mice per genotype) over-
laid with polynomial best-fit 





proportion was of a diameter of 0.5–0.6 μm, in comparison 
to that being 0.6–0.7 μm in floxed controls (Fig. 1g). A 
polynomial best-fit regression of the proportion of myeli-
nated axons per axon diameter confirmed a statistically 
significant shift towards myelination of smaller diameter 
axons in activin receptor conditional knockouts (Fig. 1g). 
All PDGFRa-Cre;  Acvr1bfl/fl mice died by P21 preclud-
ing longitudinal analysis of myelination; juvenile death 
is also a feature of some other hypomyelinating mutants 
[9, 15, 18, 34, 54, 64]. Nonetheless, analysis of mice at 
P21 showed some myelination, although hypomyelination 
was still prevalent in the corpus callosum and cerebellum 
(Online Resource Supplemental Fig. 2e). Overall, these 
data show the requirement for activin receptor signaling 




Activin receptor signaling drives oligodendrocyte 
differentiation
We next sought to determine the cellular mechanisms 
underpinning the hypomyelination in PDGFRa-Cre; 
 Acvr1bfl/fl mice, by assessing oligodendroglial responses. 
Between genotypes at P16, there were no differences 
in total oligodendroglial lineage cell number (Olig2+) 
(Fig. 2a); we did not observe cell death in the lineage 
at either P16 or earlier (cleaved caspase-3 negative and 
TUNEL negative) in any genotype (Online Resource Sup-
plemental Fig. 3), consistent with oligodendrocyte death 
normally occurring later in development [24]. How-
ever, whereas in floxed control mice, the proportion of 
Olig2+ cells that were mature oligodendrocytes (CC1+) 
was not significantly different from that which were imma-
ture cells (CC1−), PDGFRa-Cre;  Acvr1bfl/fl mice had sig-
nificantly less CC1+ Olig2+ cells versus CC1− Olig2+ 
cells (Fig. 2b), suggesting impaired differentiation into 
mature oligodendrocytes. To specifically address this, we 
quantified differentiating oligodendrocytes (cytoplasmic 
Olig1+ Olig2+ cells) and found that these were signifi-
cantly decreased in PDGFRa-Cre;  Acvr1bfl/fl mice com-
pared to controls (Fig. 2c, d). The oligodendrocyte matura-
tion defect in activin receptor conditional knockout mice 
was observed as early as P1, when few immature oligoden-
drocytes (MAG+ MBP−) cells were observed (Fig. 2e). 
These data support that activin receptor signaling is 
required for differentiation of a significant proportion of 
oligodendrocyte lineage cells.
To assess the sufficiency of activin receptor signaling in 
driving oligodendrocyte differentiation, primary cultures of 
wildtype OPCs were treated with the most potent activat-
ing ligand, activin-A. Even in the presence of proliferation-
inducing growth factors (platelet-derived growth factor and 
fibroblast growth factor) which normally preclude differen-
tiation, activin-A significantly enhanced OPC differentiation 
into mature oligodendrocytes (MAG+) (Fig. 2f, g). Consist-
ent with this finding, data-mining of the human fetal brain 
transcriptome [39] revealed that as development proceeds, 
increased gene expression of activin-A (INHBA) parallels 
that of oligodendrocyte maturation-associated genes MAG 
and MOG (Fig. 2h). The activin-A subunit (Inhba) was also 
found to be expressed in developing mouse brain during 
myelination (Online Resource Supplemental Fig. 4).
Activin receptor signaling drives oligodendrocyte 
membrane compaction
Although we demonstrated impaired oligodendrocyte 
differentiation in the activin receptor conditional mutant 
mouse, there were still some oligodendrocytes that were 
generated resulting in limited myelination taking place. 
We next analyzed whether this myelin was normally 
formed, to determine whether activin receptor signal-
ing is required for proper myelination. In PDGFRa-Cre; 
 Acvr1bfl/fl mice at P16, we observed increased myelin 
inner tongue thickness in PDGFRa-Cre;  Acvr1bfl/fl mice 
compared to floxed controls (Fig.  3a–c), most promi-
nently in association with small-diameter axons (Fig. 3b, 
c; measurement protocol outlined in Online Supplemen-
tal Resource Fig. 5). Enlarged myelin inner tongues are 
normally seen in early myelination during the active 
growth phase, resulting from accumulation of new myelin 
membrane prior to actin disassembly mediated compac-
tion and fusion with myelin sheaths [48, 60, 66]. Persis-
tent enlargement of inner tongues may thus result either 
from (i) increased membrane growth rate, or (ii) impaired 
actin disassembly and myelin membrane compaction [48, 
61, 66]. Given that the former postulate would result in 
a thicker myelin sheath, we measured thickness of com-
pacted layers (as done previously [66]; measurement pro-
tocol outlined in Online Supplemental Resource Fig. 5), 
yet documented significantly thinner myelin at all axon 
diameters in PDGFRa-Cre;  Acvr1bfl/fl mice (Fig.  3d) 
thereby ruling out increased membrane growth. The thin-
ner myelin in conditional knockout mice was confirmed 
to be compact (Fig. 3e). To address the latter postulate, 
we assessed expression of myelin basic protein (MBP), 
which is required for actin disassembly and myelin mem-
brane compaction [60, 66]. PDGFRa-Cre;  Acvr1bfl/fl mice 
Fig. 2  Activin receptor signaling regulates oligodendrocyte differ-
entiation. a Mean number of oligodendrocyte lineage cells (Olig2+) 
per field ± s.e.m. in corpus callosum of P16  Acvr1bfl/fl (n = 3 mice), 
PDGFRa-Cre;  Acvr1bfl/+ (n = 4 mice) and PDGFRa-Cre;  Acvr1bfl/fl 
mice (n  =  7 mice). b Mean proportion of oligodendrocyte line-
age cells (Olig2+) which are mature oligodendrocytes (CC1+) 
versus immature cells (CC1−), per field  ±  s.e.m. in corpus cal-
losum of P16  Acvr1bfl/fl (n  =  4 mice) and PDGFRa-Cre;  Acvr1bfl/fl 
mice (n = 7 mice). Multiple t tests with false discovery rate of 1%, 
***P  =  0.000026. c Images of differentiating oligodendrocytes 
(cytoplasmic Olig1+ and nuclear Olig2+) in corpus callosum of P16 
 Acvr1bfl/fl and PDGFRa-Cre;  Acvr1bfl/fl mice. Scale bar 25  μm. d 
Mean number of cytoplasmic Olig1 and Olig2 double positive cells 
per field ± s.e.m. in corpus callosum of P16  Acvr1bfl/fl (n = 3 mice), 
PDGFRa-Cre;  Acvr1bfl/+ (n = 4 mice) and PDGFRa-Cre;  Acvr1bfl/fl 
mice (n = 7 mice). Two-tailed Student’s t test, **P = 0.0047, 0.0026, 
respectively. e Images of maturing oligodendrocytes (MAG+ MBP−) 
at P1 in corpus callosum of  Acvr1bfl/fl and PDGFRa-Cre;  Acvr1bfl/
fl mice. Scale bar 25 μm. f Mean number of MAG+ cultured oligo-
dendrocytes per field in vehicle control-treated or activin-A-treated 
conditions (10  ng  ml−1) in  vitro. n  =  3 biological replicates. Two-
tailed paired Student’s t test, *P = 0.0484. g Images of cultured OPCs 
treated with vehicle or 10 ng ml−1 activin-A and immunostained for 
MAG (green), counterstained with Hoechst (blue). Scale bar 25 μm. 
h Data-mining of microarray of human fetal brain at 9 and 12 ges-
tational weeks (gw) represented as fold change in expression (nor-
malized to 9 gw), showing paralleled expression changes between 
activin-A (INHBA) and oligodendrocyte differentiation-associated 




Fig. 3  Activin receptor signaling regulates myelin membrane com-
paction/maturation. a Electron micrographs of myelinated axons in 
P16  Acvr1bfl/fl and PDGFRa-Cre;  Acvr1bfl/fl mice. Scale bars 1 μm. 
b Average inner tongue thickness per axon diameter per animal in 
 Acvr1bfl/fl (magenta) and PDGFRa-Cre;  Acvr1bfl/fl mice (green). 
n  =  3 mice per genotype. c Dot plot of inner tongue thickness per 
axon diameter for all myelinated axons for all animals, in  Acvr1bfl/fl 
(magenta) and PDGFRa-Cre;  Acvr1bfl/fl mice (green). d Myelin thick-
ness versus axon diameter in  Acvr1bfl/fl (magenta) and PDGFRa-Cre; 
 Acvr1bfl/fl mice (green). Extra sum of squares F test between slopes, 
***P = 0.0014. e Electron micrographs of compact myelin layers in 
P16  Acvr1bfl/fl and PDGFRa-Cre;  Acvr1bfl/fl mice. f Images of myelin 
basic protein (MBP) in corpus callosum of  Acvr1bfl/fl and PDGFRa-
Cre;  Acvr1bfl/fl mice at P16. Scale bar 25  μm. g MBP intensity in 
PDGFRa-Cre;  Acvr1bfl/fl mice normalized to background and to lev-
els in  Acvr1bfl/fl mice. s.e.m. for variance in  Acvr1bfl/fl samples indi-
cated. One sample t test against theoretical mean of 1, **P = 0.0097. 
h Image of PDGFRa-Cre;  Acvr1bfl/fl corpus callosum showing 
MAG+ (green), MBP negative (red) myelin sheaths (arrows). i Per-
centage of total axonal area (neurofilament (NF)+) co-localizing 
with compaction marker Caspr in caudal corpus callosum at P16 in 
 Acvr1bfl/fl and PDGFRa-Cre;  Acvr1bfl/fl mice. Two-tailed Student’s t 
test, **P = 0.0038, n = 2–4 mice per group. Inset example of Caspr 
clusters (green) at paranodes along axon (NF+; purple) (arrow). j 
Images of cultured mature oligodendrocytes treated with vehicle 
control or activin-A (10 ng ml−1) stained with Phalloidin-Alexa-568 
(red) and MBP (green). Scale bar 20  µm. k Phalloidin intensity 
(arbitrary units; A.U.) in MBP+ sheets of mature oligodendrocytes 
plotted against oligodendrocyte size (pixels squared;  px2) in control 
(magenta) or activin-A (10 ng ml−1) treated (green) conditions
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showed significantly decreased MBP intensity relative to 
floxed controls (Fig. 3f, g); MAG+ myelin sheaths devoid 
of MBP were also observed in these mice (Fig. 3h), indica-
tive of non-compact myelin as MAG is normally excluded 
from compact myelin sheaths by MBP [2, 3]. These data 
suggest that activin receptor signaling in oligodendroglial 
lineage cells is required for normal MBP expression and 
myelin membrane compaction.
We next asked whether this impairment in compaction 
would be maintained as myelination proceeds in the condi-
tional knockout mice. Due to these mice dying by P21, we 
addressed this by examining the caudal region of the corpus 
callosum in P16 mice, where myelination is more advanced 
relative to rostral regions. As clustering of the axonal adhe-
sion molecule Caspr along axons only occurs when myelin 
is compacted at the internode [63], we used the percentage 
of axonal area co-localizing with Caspr clusters as a read-
out of compaction. In comparison to  Acvr1bfl/fl mice, the 
percentage of total axonal area (NF+) occupied by Caspr 
clusters was significantly lower in caudal corpus callosum 
of PDGFRa-Cre;  Acvr1bfl/fl mice, indicative of a maintained 
deficiency in myelin compaction (Fig. 3i).
Given that myelin compaction requires actin disassem-
bly [48, 66], the sufficiency of activin receptor signaling 
in accelerating actin depolymerization in oligodendrocyte 
membranes was assessed. Maturing wildtype oligodendro-
cytes were treated with activin-A, and non-depolymerized 
filamentous actin was detected using fluorescently conju-
gated Phalloidin, a method established in recent studies 
of actin dynamic-driven oligodendrocyte membrane com-
paction [48, 66]. Oligodendrocyte membranes in control 
conditions had high Phalloidin signal throughout MBP+ 
membranes at 5 days of in vitro maturation, indicative of 
non-depolymerized actin (average intensity/cell 38.3 ± 0.9 
A.U.; Fig. 3j, k). Conversely, activin-A-treated oligoden-
drocyte membranes showed a reduced Phalloidin intensity, 
demonstrating increased actin depolymerization conse-
quent to activin receptor signaling (average intensity/cell of 
28.0 ± 0.5 A.U.; Fig. 3j, k).
To next test whether activin signaling regulates the total 
amount of myelin membrane made by oligodendrocytes, we 
first measured the average size of oligodendrocyte mem-
branes in activin-A-treated cultures, yet found no difference 
to vehicle-treated cultures (Fig. 3k and Online Resource 
Supplemental Fig. 6a, b). We assessed the number and 
length of myelin sheaths formed by oligodendrocytes on 
poly-L-lactic acid microfibers, and also found no significant 
effect of activin-A treatment (Online Resource Supplemental 
Fig. 6c, d). Overall these results demonstrate that although 
activin receptor signaling does not increase the amount of 
membrane produced once an oligodendrocyte has differen-
tiated, it has an important role in efficient oligodendrocyte 
membrane actin disassembly and myelin compaction.
Activin receptor subtype Acvr2a regulates 
oligodendrocyte differentiation and membrane 
actin disassembly
Having shown that signal transduction via the co-receptor 
Acvr1b is required for oligodendrocyte differentiation and 
membrane compaction, we next asked which ligand-binding 
activin receptor drives this effect. Activin-A can bind to two 
activin receptor subtypes, Acvr2a and Acvr2b; whether these 
have differential function or protein expression patterns in 
the CNS is unknown. We assessed Acvr2a and Acvr2b 
expression in the oligodendrocyte lineage during develop-
mental myelination. Acvr2a expression in the cell bodies of 
Olig2+ cells was found to progressively increase over time 
while oligodendrocyte differentiation is underway (P1–P8), 
and was later also associated with myelin at the peak of 
myelination (P14) (Fig. 4a). We detected Acvr2a expression 
in both NG2+ immature cells and CC1+ mature oligoden-
drocytes (Fig. 4b). Data-mining of oligodendrocyte lineage 
single-cell transcriptomes in later development (P21–30; 
[41]; linnarssonlab.org/oligodendrocytes) confirmed sus-
tained Acvr2a expression throughout the lineage, including 
in subsets of precursors and myelinating oligodendrocytes 
(Fig. 4c). Conversely, Acvr2b protein was not detectable at 
any time point in development (Fig. 4a), in contrast to the 
robust signal observed in positive control placental tissue 
(Online Resource Supplemental Fig. 7a) [56], and consistent 
with undetectable Acvr2b mRNA in the developing brain 
at the onset of myelination (Online Resource Supplemental 
Fig. 7b).
Given that Acvr2a is the receptor subtype expressed at 
the onset of differentiation and myelination, we next tested 
whether this receptor drives these responses by co-treating 
oligodendrocyte lineage cells with activin-A and an Acvr2a-
specific neutralizing antibody, or an isotype IgG control. 
Protein blasting the epitope sequences for the Acvr2a anti-
body showed 100% specificity and selectivity for this recep-
tor subtype. Blocking Acvr2a reversed the effects of activin-
A on differentiation of OPCs into mature oligodendrocytes 
(MBP+) (Fig. 4d, e), and prevented activin-A-driven actin 
disassembly in oligodendrocytes (causing increased Phalloi-
din intensity in MBP+ membranes; Fig. 4f, g). Conversely, 
blocking Acvr2b had no significant effect on oligodendro-
cyte differentiation (Online Resource Supplemental Fig. 8a), 
although it did reduce activin-A-driven actin disassembly 
(Online Resource Supplemental Fig. 8b). Nevertheless, this 
data revealed that Acvr2a is the activin receptor subtype 
expressed by the oligodendrocyte lineage during develop-
mental myelination and can drive activin-A-mediated oligo-
dendrocyte differentiation and membrane actin disassembly.
To next determine which signaling pathways mediate 
Acvr2a-driven oligodendrocyte differentiation and mem-
brane actin depolymerization, we assessed activation of 
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the 5 TGFβ signaling pathways induced downstream of 
activin receptors (Rac1 GTPase, p38 MAPK/JNK, PI3K/
AKT, Smad2/3, ERK1/2,) which are also associated with 
regulation of oligodendroglial lineage responses and mye-
lination [4, 27, 29, 47, 61]. Activation of all pathways in 
activin-A-stimulated oligodendroglial lineage cells was 
simultaneously assessed by measuring phosphorylation 
levels of signaling proteins using a forward-phase anti-
body microarray; phosphorylation signal was normalized 
to respective total protein signal, and values then normal-
ized to vehicle control. We found that activin-A increased 
phosphorylation signal in all pathways, with the highest 
increase in signal observed in the Rac1 GTPase and p38/
MAPK pathways (Fig. 4h). Taken together with our find-
ings, these results are consistent with known roles for 
the Rac1 GTPase and p38 MAPK pathways in regulating 
oligodendrocyte differentiation, myelination, and myelin 
compaction [11, 13, 19, 25, 29, 61].
Fig. 4  Activin receptor Acvr2a regulates oligodendrocyte lineage 
cell behavior. a Acvr2a (top row; green) and Acvr2b (bottom row; 
green) expression by oligodendrocyte lineage (Olig2+; red) through-
out development (P1–P14; double positive cells indicated by arrows), 
counterstained with Hoechst (blue). Inset; isotype control for Acvrs. 
Scale bar 50  μm. b Expression of Acvr2a (red) by NG2+ cells 
(green) (top row), and by CC1+ cells (green) (bottom row). c Data-
mining of oligodendrocyte lineage cell transcriptomes from P21–30 
for Acvr2a expression, represented as t distributed stochastic neighbor 
embedding projection. d OPCs co-treated with activin-A and neutral-
izing antibodies for Acvr2a or isotype IgG. Mean percentage of oli-
godendrocytes (MBP+) normalized to isotype control ± s.e.m. n = 3 
biological replicates, two-tailed Student’s t test, P = 0.0087. e Images 
of MBP+ cells (red) in cultures treated with activin-A (10 ng ml−1) 
and isotype IgG or Acvr2a-neutralizing IgG. Scale bar 75  μm. f 
Phalloidin intensity signal (arbitrary units; AU) per oligodendro-
cyte plotted against oligodendrocyte size  (px2) in cultures co-treated 
with activin-A (10 ng ml−1) and IgG control or neutralizing antibody 
against Acvr2a. n = 3 biological replicates. g Images of MBP+ oligo-
dendrocytes (green) and filamentous actin (Phalloidin+; red) in cul-
tures treated with activin-A and IgG or Acvr2a neutralizing antibody. 
h Log2-transformed phosphorylation signal of TGFβ superfamily 
pathways following treatment with activin-A, normalized to respec-
tive total protein signal then to vehicle control. Heat map: compared 




Activin receptor signaling regulates remyelination
Having shown the role of activin receptor signaling in 
developmental myelination, we next asked whether it is 
also relevant to regeneration of myelin following injury. Our 
previous work showed that at the onset of remyelination, 
activin-A levels increase and activin receptors are expressed 
by OPCs [45]. To examine whether this expression has func-
tional significance for remyelination, we used activin-A to 
stimulate activin receptors during remyelination of ex vivo 
organotypic cerebellar brain explants which were demyeli-
nated with lysolecithin. Activin-A significantly increased 
remyelination at 7 days post lysolecithin (dpl) compared to 
vehicle control, as measured by remyelination index (co-
localization of myelin basic protein (MBP) and axonal neu-
rofilament, normalized to area of neurofilament) [63, 65] 
(Fig. 5a, b). Due to remyelination subsequently occurring 
efficiently in controls, no significant differences between 
vehicle and activin-A-treated explants were observed at later 
time points (10, 14 dpl) (Fig. 5b). These data demonstrate 
that activin receptor stimulation is sufficient to accelerate 
remyelination. To determine whether activin receptor sign-
aling is required for remyelination, demyelinated cerebel-
lar explants were treated with an inhibitor of activin recep-
tors, inhibin-A, which competitively binds these receptors 
to prevent endogenous ligand binding [42]. Remyelination 
was significantly repressed by inhibin-A treatment at 7, 10 
and 14 dpl compared to vehicle control (Fig. 5c, d), dem-
onstrating for the first time that activin receptor signaling is 
required for remyelination.
To assess activin receptor subtype expression during effi-
cient remyelination, we took advantage of the temporally 
discrete OPC responses occurring following focal demyeli-
nated lesion induction of the caudal cerebellar peduncles. At 
the time of initiation of oligodendrocyte differentiation and 
remyelination (10 dpl), Acvr2b levels decreased and Acvr2a 
levels concomitantly increased (Fig. 5e, g); these changes in 
expression were confirmed to occur in oligodendroglial line-
age cells (NG2+, Olig2+; Fig. 5f). Non-lesioned CCP had 
no Acvr2b signal, confirming the absence of its expression 
in healthy adult white matter (Fig. 5h). Thus, in contrast to 
the absence of Acvr2b expression during development or 
homeostasis, its transient induction after demyelination is an 
early response to injury, which is followed by a transition to 
Acvr2a expression during efficient remyelination.
Activin receptor expression is dysregulated 
in non‑repairing lesions in human myelin disorders
In light of our results showing that activin receptor signal-
ing regulates developmental myelination and remyelination, 
and that activin receptor subtype expression by oligoden-
droglial lineage cells is strictly controlled following injury, 
we predicted that dysregulation of activin receptor expres-
sion may underpin chronic failure of oligodendrocyte dif-
ferentiation and myelin formation in human disorders [10, 
38]. We first investigated brain tissue from perinatal brain 
injury cases (Online Resource Supplemental Table 1) and 
compared areas of normally developing white matter (low 
microglia density: average 10 ± 10 cells/mm2) to areas of 
injury (high microglia density: average 122 ± 30 cells/mm2) 
(Online Resource Supplemental Fig. 9a–c). We observed 
increased densities of cells positive for the activin-A subunit 
INHBA in the brain parenchyma in injured vs. non-injured 
areas (Fig. 6a, b), consistent with previously reported ele-
vated INHBA in the cerebrospinal fluid following perinatal 
brain injury [23]. However, injured areas had lower densi-
ties of oligodendroglial cells (Olig2+) expressing Acvr2a, 
and higher densities of those expressing Acvr2b (Fig. 6d), 
compared to non-injured areas. This was not associated with 
a normal regenerative response to injury, as proliferating 
oligodendroglial lineage cells (PCNA+ Olig2+) were not 
increased relative to in non-injured regions (Fig. 6e).
We next examined adult progressive MS brain lesions 
with four types of pathology displaying a range of remy-
elination potential: lesions with completed remyelination 
(‘remyelinated’), ongoing damage and active remyelina-
tion (‘acute active’, rim of ‘chronic active’), and little to no 
remyelination (‘chronic inactive’) (Online Resource Supple-
mental Table 2, Online Resource Supplemental Fig. 9d–f). 
Activin-A (INHBA)+ cells were present in lesions regard-
less of pathology, yet densities were significantly increased 
in acute active lesions (Fig. 6f, g) consistent with increased 
INHBA detected in cerebrospinal fluid following recent 
adult brain injury [52]. Within actively remyelinating lesions 
(acute active and chronic active lesions), the proportion of 
Olig2+ cells that were Acvr2a+ was higher than the pro-
portion that were Acvr2b+ (Fig. 6h). However, the propor-
tion of Acvr2b+ Olig2+ cells was significantly increased in 
chronic inactive lesions (Fig. 6h), the lesions with the lowest 
remyelination potential. Thus, a common feature of lesions 
with limited oligodendrocyte differentiation and myelin gen-
eration in both developmental and adult disorders was an 
increase in Acvr2b+ oligodendroglial lineage cells. Both 
the increase in Acvr2b expression and its relatively higher 
affinity for activin-A [5] would be predicted to sequester 
the ligand thereby restricting Acvr2a-mediated signaling in 
oligodendrocyte lineage cells.
To test this hypothesis, Acvr2b was overexpressed in oli-
godendrocyte lineage cells via lentiviral delivery of a con-
struct driving expression of Acvr2b along with a membrane-
tagged green fluorescent protein (GFP) (Acvr2b-LV), and 
using a lentivirus driving GFP expression only as a control 
(control-LV). Successful transfection of OPCs at 3 days of 
exposure was confirmed by detection of GFP expression in 
99% of cells (Fig. 6k). Compared to control-LV conditions, 
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Fig. 5  Activin receptor signaling regulates remyelination. a Rep-
resentative images of organotypic cerebellar slice cultures at 7 days 
post lysolecithin-induced demyelination, treated with vehicle control 
or activin receptor agonist activin-A during remyelination, immu-
nostained against myelin basic protein (MBP; green), and axonal 
neurofilament-H (NF; red). Scale bar 50 μm. b Mean remyelination 
index  ±  s.e.m. in activin-A-treated explants at 7, 10, and 14  days 
post lysolecithin (dpl) normalized to vehicle control from the respec-
tive time point. n = 3 animals, one-sample t test compared to theo-
retical mean of 1 (control), **P  =  0.0057. c Representative images 
of slice cultures at 14 dpl treated with vehicle control or an inhibitor 
of activin receptor signaling inhibin-A during remyelination, immu-
nostained against myelin basic protein (MBP; green) and axonal 
neurofilament-H (NF; red). Scale bar 50  μm. d Mean remyelina-
tion index ± s.e.m. in inhibin-A-treated explants at 7, 10, and 14 dpl 
normalized to vehicle control from the respective time point. n = 3 
animals, one-sample t test compared to theoretical mean of 1 (con-
trol), *P  =  0.0165, *0.0374, **0.0004, respectively. e Acvr2a and 
Acvr2b expression (green) in demyelinated caudal cerebellar pedun-
cles (CCP) at 5  days post-lesion (dpl; prior to remyelination) and 
10 dpl (onset of remyelination), counterstained with Hoechst (blue). 
Scale bar 25 μm. f Colocalization of Acvr2b or Acvr2a (green) with 
NG2 (top 2 rows; red; arrowheads) or Olig2 (bottom 2 rows; red; 
arrowheads) at 5 and 10 dpl in CCP, counterstained with Hoechst 
(blue). g Mean number of cells double positive for Olig2 and Acvr2a 
or Acvr2b per field ± s.e.m. at 5 and 10 dpl. n = 3 = 4 animals per 
group. Two-tailed Student’s t test, P  =  0.0345 (5 dpl), 0.0298 (10 




overexpression of Acvr2b significantly impaired both 
activin-A-driven OPC differentiation into mature MBP+ oli-
godendrocytes (Fig. 6j, k) and actin depolymerization in 
maturing oligodendrocyte membranes (causing an increase 
in Phalloidin intensity per cell; Fig. 6l, m). These experi-
ments confirm that increased expression of Acvr2b by oligo-
dendroglial lineage cells impairs ligand-driven oligodendro-
cyte differentiation and actin dynamics involved in myelin 
compaction.
Discussion
In this study, we reveal the role of activin receptor sign-
aling in CNS myelin generation during healthy develop-
ment and following injury. Using a conditional knockout 
approach, in vitro manipulation of oligodendrocyte line-
age cells, ex vivo/in vivo modeling of remyelination, and 
human post-mortem brain tissue analysis, we uncover the 
requirement for activin receptor signaling in driving timely 
oligodendrocyte differentiation and myelin compaction, and 
its dysregulation in disease (summarized in Fig. 6n). These 
findings go beyond previous studies showing that activin 
receptor stimulation is protective for neurons [22, 30, 55], by 
demonstrating a direct and disease-relevant role in oligoden-
drocyte lineage cells. Our results also extend the functions of 
the TGFβ superfamily beyond supporting oligodendrocyte 
differentiation [19, 49] to now include regulation of myelin 
compaction and an appropriate response to white matter 
injury in human disease.
We eliminated all activin receptor responses in the oli-
godendroglial lineage by conditionally knocking out the 
co-receptor Acvr1b at the OPC stage, which would prevent 
all downstream signaling subsequent to ligand binding to 
activin receptors Acvr2a or Acvr2b. By postnatal day 16, 
this caused a 60% reduction in the number of myelinated 
axons, particularly those of intermediate caliber. This find-
ing reveals that there are activin receptor-dependent and 
-independent mechanisms driving axonal ensheathment 
with myelin membrane. This may be regulated by differen-
tial expression of activin receptor ligands across axon calib-
ers, as experimental augmentation of axon caliber to support 
myelination is associated with increased expression of the 
activin-A subunit [28]. Myelination may also be regulated by 
heterogeneity of activin receptor expression in oligodendro-
glial lineage cells, as our data-mining of a single-cell RNA 
sequencing dataset [41] showed that only a subset of cells 
express Acvr2a at each stage of oligodendrocyte maturation.
The hypomyelination in activin receptor conditional 
knockout mice was associated with reduced numbers of 
maturing oligodendrocytes, showing the requirement for 
activin receptor signaling in the differentiation of a signifi-
cant subset of oligodendroglial lineage cells. Importantly, 
activin receptor stimulation of wildtype OPCs (with activin-
A) was sufficient to enhance oligodendrocyte differentia-
tion, even in the presence of proliferation-stimulating growth 
factors. Although in the knockout some myelinating oligo-
dendrocytes were still generated, these cells demonstrated 
impaired myelin membrane compaction, as evidenced by 
a persistent enlargement of the inner tongue, thinner lay-
ers of compact myelin, and myelin sheaths devoid of the 
compaction-inducing protein MBP. In addition, stimulation 
of activin receptors on wildtype maturing oligodendrocytes 
enhanced depolymerization of actin in membranes, a pro-
cess required for myelin membrane compaction [48, 66]. 
Thus, we established that activin receptor signaling regulates 
myelination by driving oligodendrocyte differentiation and 
myelin membrane compaction, which to our knowledge is 
the first time a receptor axis has been directly linked to both 
processes.
These effects were found to be mediated by the ligand-
binding activin receptor subtype Acvr2a, as its neutralization 
in wildtype cells eliminated activin-A-driven oligodendro-
cyte differentiation and membrane actin depolymeriza-
tion. Accordingly, we showed that Acvr2a expression on 
oligodendroglial lineage cells in vivo coincides with oli-
godendrocyte differentiation and myelin generation during 
development and following injury. At the onset of successful 
remyelination, there was a concomitant downregulation of 
Acvr2b. Acvr2b has relatively higher affinity for activin-A 
compared to Acvr2a [5], and importantly its overexpression 
was found to impair activin-A-induced oligodendrocyte dif-
ferentiation and membrane actin depolymerization. Thus, 
the downregulation of Acvr2b after injury may allow Acvr2a 
to bind ligand more readily to drive oligodendroglial lineage 
responses and initiate repair.
Following CNS injury, the rapid increase in expression 
of activin-A [1, 23, 43, 62] likely represents an attempt at 
repair, supported by our previous observation of increased 
activin-A subunit expression in focal demyelinated lesions 
at the onset of remyelination [45]. However, activin-A 
(INHBA)+ cells were found to be present in both repairing 
and non-repairing regions of damaged human white mat-
ter, indicating that following injury oligodendrocyte line-
age cell responses are likely not regulated by activin-A, 
but rather by activin receptors. Indeed, regions that were 
actively myelinating (in perinatal tissue) or remyelinating 
(in multiple sclerosis lesions) demonstrated relatively higher 
densities of oligodendroglial lineage cells expressing Acvr2a 
compared to those expressing Acvr2b. However, an increase 
in Acvr2b+ oligodendroglial lineage cells was observed in 
non-repairing white matter (injured regions following peri-
natal brain injury, and chronic inactive multiple sclerosis 
lesions), which would be predicted to sequester ligand and 
consequently impair Acvr2a-regulated oligodendrocyte 





postulate, increased levels of Acvr2b mRNA in umbilical 
cord blood at birth is associated with more severe clinical 
outcome in infants following hypoxic-ischemic perinatal 
brain injury [40].
Oligodendrocyte differentiation, myelination, and remy-
elination have also been associated with activation of other 
receptors, such as endothelin receptor B [63], RXRγ [31], 
and CXCR4 [50]. As we observed both activin receptor-
dependent and -independent oligodendrocyte differentiation 
in vivo, this suggests that complementary pathways likely 
coordinate oligodendroglial lineage responses in parallel. 
This may involve distinct subsets of oligodendroglial line-
age cells preferentially expressing specific receptors; indeed 
data-mining of a single-cell RNAseq database confirms dis-
tinct expression patterns of the abovementioned receptors 
within the oligodendrocyte lineage [41] (data not shown). 
An alternate mechanism may involve context-dependent 
availability of ligand; for example, we have previously dem-
onstrated dynamic changes in activin-A protein levels dur-
ing the course of remyelination [45]. Here, we provide the 
first evidence for a receptor axis that is dysregulated in both 
myelin disorders of development (perinatal brain injury) and 
adulthood (MS), despite having distinct etiologies. These 
disorders also share dysregulation of an intracellular sign-
aling cascade, the Wnt/β-catenin pathway [20, 21], which 
may further antagonize Acvr2a signaling via upregulation 
of an inhibitor of activin-A (follistatin) [35] and a pseudo-
receptor acting as a dominant negative Acvr1b (BAMBI) 
[59]. Whereas other members of the TGFβ superfamily (e.g. 
bone morphogenic proteins) have recently been shown to 
impair remyelination via signaling through distinct receptors 
(BMPR1, Acvr1a) and pathways (Smad1/5/8) [51], our data 
demonstrate the pro-myelination/remyelination properties of 
the TGFβ superfamily via activin receptor signaling. Thus, 
we propose that therapies specifically restoring Acvr2a-
mediated signaling in oligodendroglial lineage cells could 
represent a novel strategy to enhance differentiation and 
myelin generation following CNS injury across the lifespan.
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